Market Place
Sourcing Support
Biocardia Reports 2025 Business Highlights And Financial Results
24 Mar 2026 //
GLOBENEWSWIRE
BioCardia Names Slosman CEO as Krasno Steps Down
03 Dec 2025 //
GLOBENEWSWIRE
Biocardia Appoints Farhan Shahab As VP Of Quality
24 Nov 2025 //
GLOBENEWSWIRE
Biocardia To Host Q3 2025 Corporate Update Conference Call
05 Nov 2025 //
GLOBENEWSWIRE
BioCardia`s Q2 2025 Business Highlights and Financial Results
11 Aug 2025 //
GLOBENEWSWIRE
Henry Ford Begins CardiAMP HF II Ischemic HF Study
16 Jul 2025 //
GLOBENEWSWIRE
BioCardia Reports Q1 2025 Business Highlights and Results
14 May 2025 //
GLOBENEWSWIRE
Biocardia Phase 3 CardiAMP-HF Trial Shows Improved Outcomes
31 Mar 2025 //
GLOBENEWSWIRE
BioCardia`s Conference Call on March 31, 2025 at 4:30PM EDT
31 Mar 2025 //
GLOBENEWSWIRE
BioCardia Reports 2024 Business Highlights and Financial Results
26 Mar 2025 //
GLOBENEWSWIRE
BioCardia to Host 2024 Financial Results Call on March 31, 2025
21 Mar 2025 //
GLOBENEWSWIRE
BioCardia to Host Q3 2024 Corporate Update & Financial Results
06 Nov 2024 //
GLOBENEWSWIRE
FDA Approves CardiAMP Heart Failure II Protocol Amendment
21 Aug 2024 //
GLOBENEWSWIRE
BioCardia To Host Q2 2024 Update And Results Call On August 13
07 Aug 2024 //
GLOBENEWSWIRE
BioCardia Submits Morph® DNA™ Introducer For FDA Approval
30 Jul 2024 //
GLOBENEWSWIRE
Patient Enrollment Begins In CardiAMP Cell Therapy Phase 3 Trial
25 Jul 2024 //
GLOBENEWSWIRE
BioCardia Gets US Patent For Heart Delivery Of Cell Aggregates
07 Jun 2024 //
GLOBENEWSWIRE
BioCardia Announces Reverse Stock Split
21 May 2024 //
GLOBENEWSWIRE
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
14 May 2024 //
GLOBENEWSWIRE
BioCardia Q1 2024 Call On May 14
09 May 2024 //
GLOBENEWSWIRE
BioCardia: CardiAMP Benefits In Chronic Ischemia Trial Outcomes
01 May 2024 //
GLOBENEWSWIRE
BioCardia Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
BioCardia to Host 2023 Financial Results and Corporate Update 2024
20 Mar 2024 //
GLOBENEWSWIRE
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 Mar 2024 //
GLOBENEWSWIRE
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Study
08 Feb 2024 //
GLOBENEWSWIRE
BioCardia Announces Two Scientific Abstracts Have Been Accepted at Conference
31 Jan 2024 //
GLOBENEWSWIRE
BioCardia Morph Access Innovations Development Update for Shareholders
03 Jan 2024 //
GLOBENEWSWIRE
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03
19 Dec 2023 //
GLOBENEWSWIRE
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline
18 Dec 2023 //
GLOBENEWSWIRE
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock
16 Nov 2023 //
GLOBENEWSWIRE
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol
14 Nov 2023 //
GLOBENEWSWIRE
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference
01 Nov 2023 //
GLOBENEWSWIRE
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial
11 Oct 2023 //
GLOBENEWSWIRE
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
BioCardia to Host Q2 2023 Financial Results Conference Call on August 9, 2023
02 Aug 2023 //
GLOBENEWSWIRE
BioCardia Announces FDA Completes Review Proposed Adaptive Statistical Analysis
20 Jun 2023 //
GLOBENEWSWIRE
BioCardia Announces Helix„¢ Biotherapeutic Delivery Patent Issuance in Japan
08 Jun 2023 //
GLOBENEWSWIRE
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
10 May 2023 //
GLOBENEWSWIRE
BioCardia to Host Q1 2023FYR & Corporate Update Conference Call
03 May 2023 //
GLOBENEWSWIRE
BioCardia Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
BioCardia to Host 2022 Financial Results Conference Call on March 29, 2023
16 Mar 2023 //
GLOBENEWSWIRE
Positive Echocardiography Data from BioCardia PIII Trial Presented at Meeting
06 Mar 2023 //
GLOBENEWSWIRE
BioCardia Letter to Shareholders
22 Dec 2022 //
GLOBENEWSWIRE
BioCardia Announces $3.6 Million Private Placement of Common Stock
15 Dec 2022 //
GLOBENEWSWIRE
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+
06 Dec 2022 //
BUSINESSWIRE
BioCardia off-the-shelf cell therapy to enter phase 1/2 study
06 Dec 2022 //
FIERCEBIOTECH
BioCardia to Host Q3 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial
03 Oct 2022 //
GLOBENEWSWIRE
CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data
14 Sep 2022 //
GLOBENEWSWIRE
BioCardia Announces Participation at H.C. Wainwright Global Conference
09 Sep 2022 //
GLOBENEWSWIRE
BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines
08 Sep 2022 //
GLOBENEWSWIRE
BioCardia Announces Positive DSMB Review and Recommendation to Phase III
31 Aug 2022 //
GLOBENEWSWIRE
BioCardia with BlueRock to Provide Catheter Biotherapeutic Delivery Candidates
24 Aug 2022 //
GLOBENEWSWIRE
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results
10 Aug 2022 //
GLOBENEWSWIRE
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call
04 Aug 2022 //
GLOBENEWSWIRE
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development
12 Jul 2022 //
GLOBENEWSWIRE
BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
15 Jun 2022 //
GLOBENEWSWIRE
BioCardia Reports First Quarter 2022 Business Highlights and Financial Results
11 May 2022 //
GLOBENEWSWIRE
BioCardia to Host Q1 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
